Other
Business Combination, Contingent Consideration, Liability
Vertex Pharmaceuticals Business Combination, Contingent Consideration, Liability increased by 0.3% to $79.20M in Q1 2026 compared to the prior quarter. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionOther
CategoryCapital Allocation
SignalLower is better
VolatilityModerate
First reportedQ4 2025
Last reportedQ1 2026
How to read this metric
An increase suggests the acquired business is meeting or exceeding performance targets, which will require higher future cash payouts.
Detailed definition
This represents the fair value of a liability recognized when the company is obligated to pay additional consideration t...
Peer comparison
This is a standard liability for companies pursuing aggressive M&A strategies with performance-based earn-out structures.
Metric ID:
other_business_combination_contingent_consideration_liabilityHistorical Data
2 periods
| Q4 '25 | Q1 '26 | |
|---|---|---|
| Value | $79.00M | $79.20M |
| QoQ Change | — | +0.3% |
Range$79.00M – $79.20M
Business Combination, Contingent Consideration, Liability at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's business combination, contingent consideration, liability?
- Vertex Pharmaceuticals (VRTX) reported business combination, contingent consideration, liability of $79.20M in Q1 2026.
- What does business combination, contingent consideration, liability mean?
- The estimated amount the company expects to pay in the future based on the performance of an acquired business.